Ratings for Alnylam Pharmaceuticals ALNY -1.28% Get Free Report were provided by 18 analysts in the past three months, ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 13 Biotech Stocks with Huge Upside Potential. It declared on June 9 ...

ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.

H.C. Wainwright’s Patrick Trucchio reiterated his Buy rating on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and raised his ...

The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce ...

THOU DOTH PORTEST — Protests are set to pop up around the Bay State this weekend, capping off a week of tension between the ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the European Commission (EC) to treat adults with ...

Moderna convinced a U.S. appeals court on Wednesday to uphold a ruling that undercut patent infringement claims by biotech ...

Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

ATTR-CM is a heart disease that is often undiagnosed and can be fatal. Dr. James Ampadu, a cardiologist with Prisma Health, shares symptoms of ATTR-CM. Ian, who was diagnosed with ATTR-CM, also shares ...

A local pharmaceutical company has been awarded $1.8 million through a state tax incentive program aimed at creating more ...

A local pharmaceutical company has been awarded $1.8 million through a state tax incentive program aimed at creating more ...